Bausch Health Reports Expanded Public Reimbursement For Injectable Schizophrenia Drug

12:39 PM EDT, 10/19/2026 (MT Newswires) -- Bausch Health Companies (BHC.TO) on Monday announced expanded public reimbursement for OKEDI, its anti-psychotic extended-release injectable suspension of risperidone, in 75 mg and 100 mg formulations through its Canadian subsidiary. According to a statement, coverage is now available for eligible patients through public drug plans in seven provinces and multiple federal drug plans. Okedi is indicated for the treatment of schizophrenia in adults, the statement added. "Expanding public access to treatment options is central to how we support Canadians living with schizophrenia," said Amy Cairns, general manager at Bausch Health, Canada. "We are pleased that OKEDI is now accessible to eligible patients through public drug plans in seven provinces and through federal drug plans, and we remain committed to working with provinces and territories to further expand access across Canada." Bausch Health shares were last seen down CA$0.02 at CA$8.91 on the Toronto Stock Exchange. Price: 8.91, Change: -0.02, Percent Change: -0.17